Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Succeeds As California Court Temporarily Blocks Pay-For-Delay Law

Court ‘Cannot Reasonably Find’ That Bill Regulates California Commerce Alone

Executive Summary

A judge in California has agreed to instate a temporary injunction against a state law designed to curb so-called ‘pay-for-delay’ deals, handing victory to generics and biosimilars industry association the AAM.

You may also be interested in...



AAM Opposes Oregon’s SB 764 Settlements Bill

Proposed state legislation restricting patent settlements set out in Oregon’s SB 764 bill is “unnecessary,” the AAM has insisted, opposing the “unconstitutional” legislation by citing delayed patient access to affordable medicines, the obstruction of expedited patent settlements and benefits to brand-name pharmaceutical companies which will eventually lead to price rises. 

HHS Secretary Nominee Becerra Plans ‘Swift’ Action On Drug Pricing Reform

‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’

Timeline Set For Latest AAM California Challenge

A court timeline has been set out for the latest attack by the AAM on Californian legislation that deems “pay-for-delay” litigation settlement deals anticompetitive.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

GB151492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel